Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company

Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company
• Celemics enters the Chinese DNA Sequencing market since its establishment

• NGS-based BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time

• The agreement scale is equivalent to 87% in celemics’ annual revenue

July 13, 2021 – Seoul, Korea – Celemics, Inc. (www.celemics.com), an NGS-based sequencing solution and bioinformatics company, Co-CEO Young-hoon Lee and Hyo-ki Kim announced on July 14th that Celemics has signed an annual supply agreement to provide 4.5 billion KRW ($3.9 million) worth BTSeq™ solution with Tsingke Biological Technology Co., Ltd. (Tsingke), a professional Beijing-based Sanger sequencing and gene synthesis service company.

The agreement scale is equivalent to 87% of Celemics’ annual sales of 5.2 billion KRW ($4.5 million) in 2020, which is the largest single contract that Celemics has signed since expanding to the global market in 2017. Celemics will provide BTSeq™ reagents and analysis software, a proprietary genomics analysis platform, in China to Tsingke.

Celemics’ technology supplied to Tsingke with this agreement is BTSeq™ (Barcode Tagged Sequencing) which utilizes NGS technology and Celemics’ proprietary sample preparation reagents and de novo assembly bioinformatics software. BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time. With the conventional method, Sanger sequencing, the sequencing of a few kb to 20 kb-long DNA takes several days to a few weeks and requires multiple sequencing runs and primer syntheses with high cost. BTSeq™ overcomes these challenges and enables accurate sequencing of 20 kg-long or longer DNA within 24 hours. With Celemics proprietary reagents and bioinformatics, the cost for NGS-based sequencing and the time required for analysis is significantly reduced.

Tsingke, Celemics’ Chinese partner for the Chinese genome analysis market, is a professional DNA synthesis and sequencing company established in 2004. Tsingke has 19 subsidiaries in China, including Beijing, Shanghai and Guangzhou and is a large-scale business proceeding with about 15 million DNA synthesis and sequencing cases annually. Tsingke conducted thorough validation with various samples in its affiliated companies in Nanjing, Tianjin, etc. to check the BTSeq™ performance and purchased large volume of reagent and analysis software for beta operation. After about a year of the rigorous validation period, Tsingke decided to introduce Celemics’ BTSeq™ solution.

“We expect to secure exclusive competitiveness in DNA synthesis and sequencing service with the new Celemics’ sequencing technology, BTSeq™, and will pioneer diverse application markets with Celemics.” – Tsingke CEO Ma Shijin

“Celemics is delighted to enter the Chinese NGS market through scrupulous examinations, which reassure the competitiveness of BTSeq™. Celemics will take this contract as a stepping stone to expand our contribution for researchers and companies in the fast-growing Chinese DNA sequencing market with 1.4 billion population.” – Celemics Co-Founder & CEO Hyoki Kim

Meanwhile, Celemics has been continuously and successfully preparing to expand to the global market. Celemics has recently completed designating distributors in countries such as Spain, Portugal, United Arab Emirate (UAE) and Japan and concluded partnership arrangements with distinguished international companies.

Additional Information

About Celemics: Celemics is a Korea-based biomaterial technology leader that has developed a range of innovative biomaterials and sequencing methods for use in the medical, pharmaceutical, microbiome, synthetic biology, and breeding fields. Since its founding in 2010, the company has developed Massively Separated and Sequence Identified Cloning (MSSIC™), a highly efficient massive cloning technology that serves as a foundation technology for Celemics solutions. The company has also developed Barcode-Tagged Sequencing (BTSeq™), a novel sequencing methodology established as a high-quality alternative to Sanger sequencing, and TrueRepertoire™ aimed to help vaccine developers accelerate antibody excavation. Celemics is currently the only NGS-based Target Capture Kits manufacturer in Europe, Asia, and the Middle East.


Celemics Marketing Team
+82 2 6966 0175
Email: smkim@celemics.com

Media Contact
Company Name: Celmics, Inc
Contact Person: Marketing Team
Email: Send Email
Phone: +82 2 6966 0175
Country: South Korea
Website: www.celemics.com